Fairvalue-Calculator Fairvalue-Calculator
EN DE

ENCell Co (456070) Fair Value & Analysis

Healthcare · KR · Market cap 95.9B KRW

Price7,850 KRW
Fair Value10,843 KRW
Upside+38.1%
Quality95/100
Evidence: Low Range 8,132 KRW – 13,554 KRW

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

ENCell Co (456070) currently trades at 7,850 KRW, while our model-based Fair Value estimate is 10,843 KRW — implying the stock looks roughly 38.1% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

ENCell Co., Ltd. develops cell/gene-based biopharmaceutical products in South Korea. The company develops EN00, an allogeneic umbilical cord-derived mesenchymal stem cell treatment for Charcot-Marie-Tooth disease. It also provides contracting development and manufacturing services for biopharmaceutical products. The company was founded in 2018 and is based in Seoul, South Korea.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is ENCell Co (456070) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 10,843 KRW versus a price of 7,850 KRW — about +38% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 456070?
Our 21-model fair value for ENCell Co is 10,843 KRW (as of Jun 24, 2026), built from audited fundamentals. The current price is 7,850 KRW.
What is the quality score of 456070?
ENCell Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.